106 related articles for article (PubMed ID: 24045777)
1. A novel treatment regimen for Duchenne muscular dystrophy.
Li M; Cai Y; Zhong M; Zou L; Gong C
Neuroreport; 2013 Nov; 24(16):924-7. PubMed ID: 24045777
[TBL] [Abstract][Full Text] [Related]
2. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
[TBL] [Abstract][Full Text] [Related]
3. Normal height and weight in a series of ambulant Duchenne muscular dystrophy patients using the 10 day on/10 day off prednisone regimen.
ten Dam K; de Groot IJ; Noordam C; van Alfen N; Hendriks JC; Sie LT
Neuromuscul Disord; 2012 Jun; 22(6):500-4. PubMed ID: 22390890
[TBL] [Abstract][Full Text] [Related]
4. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy.
Daftary AS; Crisanti M; Kalra M; Wong B; Amin R
Pediatrics; 2007 Feb; 119(2):e320-4. PubMed ID: 17272595
[TBL] [Abstract][Full Text] [Related]
5. Early prednisone treatment in Duchenne muscular dystrophy.
Merlini L; Cicognani A; Malaspina E; Gennari M; Gnudi S; Talim B; Franzoni E
Muscle Nerve; 2003 Feb; 27(2):222-7. PubMed ID: 12548530
[TBL] [Abstract][Full Text] [Related]
6. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China.
Hu J; Ye Y; Kong M; Hong S; Cheng L; Wang Q; Qin J; Zou L; Jiang L
Muscle Nerve; 2015 Dec; 52(6):1001-7. PubMed ID: 25809413
[TBL] [Abstract][Full Text] [Related]
7. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
[TBL] [Abstract][Full Text] [Related]
8. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.
Escolar DM; Hache LP; Clemens PR; Cnaan A; McDonald CM; Viswanathan V; Kornberg AJ; Bertorini TE; Nevo Y; Lotze T; Pestronk A; Ryan MM; Monasterio E; Day JW; Zimmerman A; Arrieta A; Henricson E; Mayhew J; Florence J; Hu F; Connolly AM
Neurology; 2011 Aug; 77(5):444-52. PubMed ID: 21753160
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
[TBL] [Abstract][Full Text] [Related]
10. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study.
Banerjee B; Sharma U; Balasubramanian K; Kalaivani M; Kalra V; Jagannathan NR
Magn Reson Imaging; 2010 Jun; 28(5):698-707. PubMed ID: 20395096
[TBL] [Abstract][Full Text] [Related]
11. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
Escolar DM; Buyse G; Henricson E; Leshner R; Florence J; Mayhew J; Tesi-Rocha C; Gorni K; Pasquali L; Patel KM; McCarter R; Huang J; Mayhew T; Bertorini T; Carlo J; Connolly AM; Clemens PR; Goemans N; Iannaccone ST; Igarashi M; Nevo Y; Pestronk A; Subramony SH; Vedanarayanan VV; Wessel H;
Ann Neurol; 2005 Jul; 58(1):151-5. PubMed ID: 15984021
[TBL] [Abstract][Full Text] [Related]
12. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
Beenakker EA; Fock JM; Van Tol MJ; Maurits NM; Koopman HM; Brouwer OF; Van der Hoeven JH
Arch Neurol; 2005 Jan; 62(1):128-32. PubMed ID: 15642859
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of corticosteroid therapy on cardiac and skeletal muscles in muscular dystrophies.
Hussein G; Mansour L; Ghafar HA; Mostafa FA; Fawaz L
J Investig Med; 2014 Aug; 62(6):875-9. PubMed ID: 24866459
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
[TBL] [Abstract][Full Text] [Related]
15. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
[TBL] [Abstract][Full Text] [Related]
16. Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy.
Buyse GM; Goemans N; van den Hauwe M; Meier T
Pediatr Pulmonol; 2013 Sep; 48(9):912-20. PubMed ID: 23129412
[TBL] [Abstract][Full Text] [Related]
17. Systemic administration of PRO051 in Duchenne's muscular dystrophy.
Goemans NM; Tulinius M; van den Akker JT; Burm BE; Ekhart PF; Heuvelmans N; Holling T; Janson AA; Platenburg GJ; Sipkens JA; Sitsen JM; Aartsma-Rus A; van Ommen GJ; Buyse G; Darin N; Verschuuren JJ; Campion GV; de Kimpe SJ; van Deutekom JC
N Engl J Med; 2011 Apr; 364(16):1513-22. PubMed ID: 21428760
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
[TBL] [Abstract][Full Text] [Related]
20. Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy.
Wood CL; Cheetham TD; Hollingsworth KG; Guglieri M; Ailins-Sahun Y; Punniyakodi S; Mayhew A; Straub V
BMC Pediatr; 2019 Apr; 19(1):131. PubMed ID: 31023296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
